Center for Colorectal Cancer, National Cancer Center, Goyang, Korea.
Dis Colon Rectum. 2012 Jun;55(6):686-94. doi: 10.1097/DCR.0b013e3182505080.
Preoperative chemoradiotherapy has become a standard treatment modality for locally advanced rectal cancer. Favorable long-term outcomes have been reported for patients with good responses to chemoradiotherapy. Therefore, predictive factors for chemoradiotherapy responses can be useful for their applicability to risk-adaptive therapy in patients with colorectal cancer.
The aim of this study was to investigate whether hydroxymethylglutaryl-coenzyme A synthase 2, a key enzyme in ketogenesis, is associated with the responses of colorectal cancer cells to chemoradiotherapy.
Hydroxymethylglutaryl-coenzyme A synthase 2 was identified by a 2-dimensional gel electrophoresis -based proteome analysis. It was analyzed in 12 colorectal cancer cells for associations with radiation or 5-fluorouracil susceptibility by Western blotting, 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium Bromide assay, and small interfering RNA transfection. Then, tumor tissues obtained from 45 patients with rectal cancer before chemoradiotherapy were analyzed by Western blotting for associations with chemoradiotherapy responses.
Expression of hydroxymethylglutaryl-coenzyme A synthase 2 was significantly correlated with intrinsic radiation resistance of 12 cancer cells. Hydroxymethylglutaryl-coenzyme A synthase 2 expression was significantly affected by treatment with either 5-fluorouracil or radiation depending on cell types. The artificial suppression of hydroxymethylglutaryl-coenzyme A synthase 2 did not result in the change of chemoradiation susceptibility in colorectal cancer cells. Nevertheless, in multivariate analyses, hydroxymethylglutaryl-coenzyme A synthase 2 expression in rectal cancer tissues was shown to be a significant predictive factor for chemoradiotherapy responses, as evaluated in terms of tumor regression grade and downstaging.
Overall findings in vitro showed that the expression level of hydroxymethylglutaryl-coenzyme A synthase 2 was highly variable depending on colon cancer cell types, and it cannot directly affect on chemoradiotherapy responses. The molecular mechanism underpinning the association between hydroxymethylglutaryl-coenzyme A synthase expression and chemoradiotherapy responses needs to be elucidated through future research.
Hydroxymethylglutaryl-coenzyme A synthase 2 was associated with the effects of chemoradiotherapy on human colorectal cancer cells. Pretreatment levels of hydroxymethylglutaryl-coenzyme A synthase 2 in rectal cancer may be useful in predicting the responses to chemoradiotherapy.
术前放化疗已成为局部晚期直肠癌的标准治疗方法。对于对放化疗有良好反应的患者,已报道了良好的长期结果。因此,放化疗反应的预测因素可用于对结直肠癌患者的风险适应治疗的适用性。
本研究旨在探讨酮体生成的关键酶羟甲基戊二酰辅酶 A 合酶 2 是否与结直肠癌细胞对放化疗的反应有关。
通过基于 2- 维凝胶电泳的蛋白质组分析鉴定羟甲基戊二酰辅酶 A 合酶 2。通过 Western blot、3-[4,5- 二甲基噻唑-2-基]-2,5- 二苯基四氮唑溴盐测定和小干扰 RNA 转染分析,对 12 种结直肠癌细胞进行分析,以确定其与辐射或 5- 氟尿嘧啶敏感性的关系。然后,通过 Western blot 分析 45 例直肠癌患者化疗前肿瘤组织与放化疗反应的关系。
羟甲基戊二酰辅酶 A 合酶 2 的表达与 12 种癌细胞的固有辐射抗性显著相关。羟甲基戊二酰辅酶 A 合酶 2 的表达受 5- 氟尿嘧啶或辐射的影响,具体取决于细胞类型。人工抑制羟甲基戊二酰辅酶 A 合酶 2 不会导致结直肠癌细胞对放化疗敏感性的变化。然而,在多变量分析中,羟甲基戊二酰辅酶 A 合酶 2 在直肠癌细胞中的表达被证明是放化疗反应的一个显著预测因子,可根据肿瘤消退分级和降期进行评估。
体外总体研究结果表明,羟甲基戊二酰辅酶 A 合酶 2 的表达水平高度依赖于结直肠癌细胞类型,并且不能直接影响放化疗反应。羟甲基戊二酰辅酶 A 合酶表达与放化疗反应之间关联的潜在分子机制需要通过进一步研究来阐明。
羟甲基戊二酰辅酶 A 合酶 2 与人类结直肠癌细胞的放化疗效果有关。直肠癌细胞中羟甲基戊二酰辅酶 A 合酶 2 的预处理水平可能有助于预测放化疗反应。